- £218.75bn
- £236.77bn
- $54.07bn
- 78
- 14
- 98
- 73
REG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 31
AnnouncementREG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 32
AnnouncementREG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 33
AnnouncementREG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 34
AnnouncementREG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 30
AnnouncementREG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 29
AnnouncementREG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 28
AnnouncementREG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 27
AnnouncementREG - AstraZeneca PLC - Total Voting Rights <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - AZ REPORTS TOP-LINE RESULT OF TREMELIMUMAB TRIAL <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - AZ enters licensing agreement with CMS for Plendil <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - ACALABRUTINIB ORPHAN DRUG DESIGNATION RECOMMENDED <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - BRILIQUE APPROVED IN EU FOR HEART ATTACK PATIENTS <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - ZURAMPIC APPROVED IN EU FOR GOUT PATIENTS <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - Durvalumab granted BTD by FDA for cancer patients <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - NEW EXTERNAL BOARD APPOINTMENT <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - AstraZeneca Full-Year and Q4 2015 Results <Origin Href="QuoteRef">AZN.L</Origin> - Part 3
AnnouncementREG - AstraZeneca PLC - AstraZeneca Full-Year and Q4 2015 Results <Origin Href="QuoteRef">AZN.L</Origin> - Part 4
Announcement